Log In Sign up
The largest database of trusted experimental protocols

Nod scid il2rγ null

Manufactured by Jackson ImmunoResearch
Visit Supplier
Sourced in United States, Montenegro

The NOD-scid IL2Rγ null is a type of immunodeficient mouse model. It is characterized by the absence of functional T cells, B cells, and natural killer cells, which makes it a useful tool for various biomedical research applications.

Automatically generated - may contain errors

Lab products found in correlation

Matrigel, by Merck Group (2 mentions) Matrigel, by Corning (1 mentions) Nod cg prkdcscid il2rgtm1wjl szj mice, by Jackson ImmunoResearch (1 mentions) Mt mg, by Jackson ImmunoResearch (1 mentions) C57bl 6, by Jackson ImmunoResearch (1 mentions)

8 protocols using nod scid il2rγ null

1

Xenograft Tumor Treatment in NSG Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animals were housed and handled in accordance with the guidelines of City of Hope Institutional Animal Care and Use Committee. The experiments described here were specifically approved by Institutional Animal Care and Use Committee protocols #07049 and #17118. Female and male 6-week-old NSG mice (NOD-scid IL2Rγ null) were purchased from Jackson Laboratory (Sacramento, CA). Hut78 cells were used for developing CTCL xenograft tumors. Briefly, 5 million cells in 100 μl (50% Matrigel/50% phosphate buffered saline; Sigma-Aldrich) were injected subcutaneously into the right flank of each mouse, and tumor development was monitored every other day. Once the tumors are were palpable and reached 100 mm3 in volume, treatment was commenced. Male and female mice, aged 8–12 weeks and with mass of 20–25 g, were divided into 3 groups (seven mice each group): control group 1 received saline containing 2% DMSO, group 2 was treated with 2 mg/kg F7/PIK75, and group 3 was treated with 10 mg/kg F7/PIK75. Mice were treated every 2 days via intraperitoneal injection. Tumors were measured twice per week using calipers. Animals were sedated and killed once tumors reached 30 mm in diameter or if any animal lost more than 20% body weight or exhibited any severe pain/distress signs that matched premature death criteria.
Zhang X.H., Nam S., Wu J., Chen C.H., Liu X., Li H., McKeithan T., Gong Q., Chan W.C., Yin H.H., Yuan Y.C., Pillai R., Querfeld C., Horne D., Chen Y, & Rosen S.T. (2018). Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma. The Journal of investigative dermatology, 138(11), 2377-2387.
+ Open protocol
+ Expand
2

Xenograft Tumor Treatment in NSG Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animals were housed and handled in accordance with the guidelines of City of Hope Institutional Animal Care and Use Committee. The experiments described here were specifically approved by Institutional Animal Care and Use Committee protocols #07049 and #17118. Female and male 6-week-old NSG mice (NOD-scid IL2Rγ null) were purchased from Jackson Laboratory (Sacramento, CA). Hut78 cells were used for developing CTCL xenograft tumors. Briefly, 5 million cells in 100 μl (50% Matrigel/50% phosphate buffered saline; Sigma-Aldrich) were injected subcutaneously into the right flank of each mouse, and tumor development was monitored every other day. Once the tumors are were palpable and reached 100 mm3 in volume, treatment was commenced. Male and female mice, aged 8–12 weeks and with mass of 20–25 g, were divided into 3 groups (seven mice each group): control group 1 received saline containing 2% DMSO, group 2 was treated with 2 mg/kg F7/PIK75, and group 3 was treated with 10 mg/kg F7/PIK75. Mice were treated every 2 days via intraperitoneal injection. Tumors were measured twice per week using calipers. Animals were sedated and killed once tumors reached 30 mm in diameter or if any animal lost more than 20% body weight or exhibited any severe pain/distress signs that matched premature death criteria.
Zhang X.H., Nam S., Wu J., Chen C.H., Liu X., Li H., McKeithan T., Gong Q., Chan W.C., Yin H.H., Yuan Y.C., Pillai R., Querfeld C., Horne D., Chen Y, & Rosen S.T. (2018). Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma. The Journal of investigative dermatology, 138(11), 2377-2387.
+ Open protocol
+ Expand
3

Xenograft Mouse Model for NEK8 Knockdown

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal experiments were approved by the Seoul National University Institutional Animal Care and Use Committee under protocol #SNU 15112–3. Experiments were conducted in accordance with relevant guidelines, including the ARRIVE guidelines (https://arriveguidelines.org).
Briefly, 6–8-week-old female NSG mice (NOD/SCID/IL-2Rγnull; Jackson Laboratory, Bar Harbor, ME, USA) were xenografted with 106 shRNA-transfected cells via subcutaneous inoculation into the mammary fat pad. Tumour growth was measured weekly using callipers, and volumes were calculated. Mice were euthanised after 35 days via CO2 inhalation. Tumours, lungs, and livers were harvested and fixed in 10% formalin (Biosesang, Seongnam, Korea).
Then, lungs and livers were prepared for paraffin sectioning and the sections were stained with H&E. The tumours were prepared for immunohistochemistry using the anti-NEK8 antibodies. For limiting dilution assays, serial dilutions (106, 104, and 102) of either Ctrl or NEK8-knockdown MDA-MB-231 cells were injected into the mammary fat pads of NSG mice.
Kang E., Kim H.K., Lee H.B, & Han W. (2023). Never in mitosis gene A-related kinase-8 promotes proliferation, migration, invasion, and stemness of breast cancer cells via β-catenin signalling activation. Scientific Reports, 13, 6829.
+ Open protocol
+ Expand
4

Xenograft Model for NSG Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female NSG (NOD-scid IL2Rγnull; Jackson Laboratory; RRID: IMSR_JAX:005557) mice of 4–6 weeks of age were purchased and housed at the animal care facility at Massachusetts General Hospital (MGH). All procedures were approved by the MGH Institutional Animal Care and Use Committee (IACUC) and conformed to NIH guidelines. Cohorts of xenografts were created to account for a 10% attrition rate and experimental groups were randomly assigned after tumors were established. Tumor size was tracked with digital calipers and mouse weights were recorded using a digital scale throughout the experiment.
Gopal R.K., Vantaku V.R., Panda A., Reimer B., Rath S., To T.L., Fisch A.S., Cetinbas M., Livneh M., Calcaterra M.J., Gigliotti B.J., Pierce K.A., Clish C.B., Dias-Santagata D., Sadow P.M., Wirth L.J., Daniels G.H., Sadreyev R.I., Calvo S.E., Parangi S, & Mootha V.K. (2023). Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma. Cancer Discovery, 13(8), 1904-1921.
+ Open protocol
+ Expand
5

Prostate Cancer Xenograft Model in NSG Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal care and studies were performed in accordance with an approved Fred Hutchinson Cancer Research Center Institutional Animal Care and Use Committee protocol and Comparative Medicine regulations. Six-week old, male NSG (NOD-SCID-IL2Rγ-null, RRID:BCBC_4142) mice were obtained from the Jackson Laboratory. 5 × 106 cells from each prostate cancer cell line were suspended in 100 μl of cold Matrigel (Corning) and implanted by injection subcutaneously into NSG mice. For LuCaP PDXs, a 1 mm3 piece of prostate tumor tissue was surgically implanted subcutaneously into NSG mice. Mice were enrolled into a treatment arm when tumors reached 150 mm3 and treated by intraperitoneal injection at the frequency and with the doses described. Labetuzumab govitecan and h679-SN-38 doses were prepared fresh through reconstitution with 0.9% preservative-free sodium chloride (McKesson Medical-Surgical). Cisplatin and etoposide (NIH Developmental Therapeutics Program, RRID:SCR_003057) were prepared and stored at room temperature and 4°C, respectively. Mice were monitored biweekly for tumor growth, weight, and body condition score. A complete response is defined as an undetectable tumor.
DeLucia D.C., Cardillo T.M., Ang L., Labrecque M.P., Zhang A., Hopkins J.E., De Sarkar N., Coleman I., da Costa R.M., Corey E., True L.D., Haffner M.C., Schweizer M.T., Morrissey C., Nelson P.S, & Lee J.K. (2020). Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(3), 759-774.
+ Open protocol
+ Expand
6

NSG Mouse Model for Biomedical Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Murine experiments presented hereafter were conducted with approval of The Salk Institute Institutional Animal Care and Use Committee (IACUC), under the protocol#08–025. NOD.Cg-PrkdcscidIl2rgtm1Wjl /SzJ mice (or NOD-Scid IL2rγnull abbreviated as NSG; age, 7 weeks; males and females; weight, 20 g) were purchased from the Jackson Laboratory, housed in air-flow racks on a restricted access area and maintained on a 12-h light/dark cycle at a constant temperature (22±1 °C). For all experiments involving the use of animals, no inclusion/exclusion criteria were applied in the present study.
Sancho-Martinez I., Nivet E., Xia Y., Hishida T., Aguirre A., Ocampo A., Ma L., Morey R., Krause M.N., Zembrzycki A., Ansorge O., Vazquez-Ferrer E., Dubova I., Reddy P., Lam D., Hishida Y., Wu M.Z., Esteban C.R., O'Leary D., Wahl G.M., Verma I.M., Laurent L.C, & Izpisua Belmonte J.C. (2016). Establishment of human iPSC-based models for the study and targeting of glioma initiating cells. Nature Communications, 7, 10743.
+ Open protocol
+ Expand
7

NOD/SCID/IL2rγnull Mouse Transplantation

Check if the same lab product or an alternative is used in the 5 most similar protocols
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD/SCID) mouse strain harbouring a null mutation of the common cytokine receptor γ chain (Il2rgtm1Wjl) (NOD/SCID/IL2rγnull) from Jackson Laboratory (Bar Harbor, ME) was used for cell transplantation. All procedures were performed on male mice between 8 and 10 weeks of age. Briefly, mice were anaesthetized with 2.5% avertin, and 2 × 106 ISL1+ CVPs were injected into the kidney capsule using an 18G tuohy epidural needle.
Soh B.S., Ng S.Y., Wu H., Buac K., Park J.H., Lian X., Xu J., Foo K.S., Felldin U., He X., Nichane M., Yang H., Bu L., Li R.A., Lim B, & Chien K.R. (2016). Endothelin-1 supports clonal derivation and expansion of cardiovascular progenitors derived from human embryonic stem cells. Nature Communications, 7, 10774.
+ Open protocol
+ Expand
8

Embryonic Lineage Tracing in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
In our experiments, we used embryos from a Rosa26Tomato/CFP male crossed to a Rosa26wt/wt (C57Bl/6; Jackson Laboratory; stock no. 00664) female. Rosa26Tomato/CFP males were generated from a cross between Rosa26Tomato/Tomato (mT/mG; Jackson Laboratory; stock no. 007576) and Rosa26CFP/CFP (TM5; generous donation by Dr. Irving Weissman). NSG (NOD-scid IL-2Rγnull; Jackson Laboratory; Stock no. 005557) mice were used as neonatal recipients. All strains were maintained at the Gross Hall and Med Sci A vivarium facilities at UCI and fed with standard chow and water. All animal procedures were approved by the International Animal Care and Use Committee (IACUC) and University Laboratory Animal Resources (ULAR) of University of California, Irvine.
Karimzadeh A., Varady E.S., Scarfone V.M., Chao C., Grathwohl K., Nguyen P.U., Ghorbanian Y., Weissman I.L., Serwold T, & Inlay M.A. (2021). Absence of CD11a Expression Identifies Embryonic Hematopoietic Stem Cell Precursors via Competitive Neonatal Transplantation Assay. Frontiers in Cell and Developmental Biology, 9, 734176.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!